Hostname: page-component-7b7567c8c-48dgx Total loading time: 0 Render date: 2026-11-18T04:46:13.824Z Has data issue: false hasContentIssue false

A systematic review of economic evaluations for RPE65-mediated inherited retinal disease including HTA assessment of broader value

Published online by Cambridge University Press:  14 June 2023

Maria Farris*
Affiliation:
Market Access Department, Novartis Pharmaceuticals Australia, Macquarie Park, Australia
Stephen Goodall
Affiliation:
Centre for Health Economic Research and Evaluation, University of Technology Sydney, Ultimo, Australia
Richard De Abreu Lourenco
Affiliation:
Centre for Health Economic Research and Evaluation, University of Technology Sydney, Ultimo, Australia
*
Corresponding author: Maria Farris; Email: Maria.H.Kokoszka@alumni.uts.edu.au
Rights & Permissions [Opens in a new window]

Abstract

Objective

To summarize the key methodological challenges identified by health technology assessment (HTA) agencies assessing gene therapy (GT) and consideration of broad elements of value.

Method

Economic evaluations (EEs) of voretigene neparvovec (VN) in RPE65-mediated inherited retinal disease (IRD) published in English were selected. HTA evaluations from Australia, Canada, Ireland, Scotland, England, and the United States were reviewed. An existing methodological framework was used to identify the challenges and considerations.

Results

Eight unique EEs were identified of which six were evaluated by HTA agencies. Incremental cost-effectiveness ratios ranged from $68,951 to $643,813 per quality-adjusted life-years (QALY) gained (healthcare perspective) and dominant to $480,130 per QALY gained (societal perspective). The key challenges were the lack of validated surrogate outcome, utility values and indirect costs from IRD patients, and limited evidence of the long-term treatment effect. Two HTA agencies reviewed a range of novel broader elements of value and whether they were associated with VN while other agencies discussed some elements of broader value. Caregiver disutility was included in some, but not all, evaluations.

Conclusion

The methodological challenges were consistent with innovative interventions for rare diseases and managed using standard methods. Broader value was important to decision-makers but inconsistently applied across agencies. Possible reasons are limitations in the evidence available of the broader benefits that VN offers and how to incorporate these within an EE. A need exists for greater guidance and consistency across jurisdictions regarding the consideration of broader value that considers latest best practice.

Information

Type
Assessment
Copyright
© The Author(s), 2023. Published by Cambridge University Press
Figure 0

Figure 1.PRISMA flowchart of the number of records included in this review.

Figure 1

Table 1.Results of economic evaluations

Figure 2

Table 2.Summary of healthcare and societal costs incorporated in voretigene neparvovec economic models

Figure 3

Table 3.Summary of voretigene neparvovec economic modeling challenges and management by reimbursement agency

Figure 4

Table 4.Details of reimbursement decisions for voretigene neparvovec

Supplementary material: File

Farris et al. supplementary material

Table S1

Download Farris et al. supplementary material(File)
File 20 KB
Supplementary material: File

Farris et al. supplementary material

Table S2

Download Farris et al. supplementary material(File)
File 23.9 KB